Key Facts and Data Points

  • Financial outlay: Rs 10,000 crore for 5 years (FY 2026‑27 to FY 2030‑31)
  • Target: Transform India into a USD 100 billion biotech industry by 2025 and capture 5 % of global pharmaceutical market share.
  • Disease focus: Affordable biologics for non‑communicable diseases (NCDs) – cancer, diabetes, autoimmune disorders (NCDs cause 63 % of deaths in India).
  • Infrastructure:
  • 3 new NIPERs (National Institutes of Pharmaceutical Education & Research) to be set up.
  • 7 existing NIPERs upgraded as centres of excellence.
  • >1,000 accredited clinical trial sites to accelerate drug development.
  • Regulatory reform: Creation of a Scientific Review Cadre in the CDSCO to align approval timelines with international standards.
  • NAMs promoted: Organ‑on‑a‑Chip, Organoids, 3‑D Bioprinting, In‑silico AI models, Ex‑vivo human tissue systems.
  • Pharma sector snapshot (Economic Survey 2025‑26):
  • Turnover Rs 4.72 lakh crore in FY 25.
  • 10,500+ manufacturing units.
  • 7 % CAGR in exports over the last decade.
  • India is the 3rd largest producer by volume (11th by value) and supplies 20 % of global generic medicines.

Background and Context

  • The National Biopharma Mission (NBM) 2017 set the vision of a $100 bn biotech sector and 5 % global share.
  • Rising NCD prevalence and potential US tariffs (100‑250 %) on branded drugs highlighted the need for self‑reliance in high‑value biologics.
  • Traditional animal testing is costly, time‑consuming, and often fails to predict human outcomes (e.g., 2006 Northwick Park trial).
  • Non‑Animal Methodologies (NAMs) offer human‑relevant data, reduce development costs by 10‑26 %, and shorten candidate identification by ~20 %.

Significance for India / Governance / Policy

  • Health security: Domestic production of biologics reduces import dependence, ensuring affordable treatment for NCDs.
  • Economic impact: Boosts exports, creates high‑skill jobs, and moves India up the value chain from generic volume to high‑value biologics.
  • Regulatory modernization: Empowering CDSCO with a scientific review cadre aligns India with International Council for Harmonisation (ICH) standards.
  • Research ecosystem: New and upgraded NIPERs, plus a national clinical trial network, foster academia‑industry collaboration.
  • Ethical advantage: Adoption of NAMs aligns with the 3Rs (Replace, Reduce, Refine), reducing animal use in research.

Related Constitutional / Legal Provisions

  • Drugs and Cosmetics Act, 1940 and Rules 1945 – governing drug approval and safety.
  • New Drugs and Clinical Trials (Amendment) Rules, 2023 – formally recognize NAMs as valid alternatives to animal data.
  • National Health Policy 2017 – emphasizes indigenous drug development and self‑reliance.
  • Make in India initiative – provides the broader policy framework for domestic manufacturing.

Non‑Animal Methodologies (NAMs) – Quick Primer

  • Organ‑on‑a‑Chip (OoC): Microfluidic devices mimicking organ physiology.
  • Organoids: 3‑D mini‑organs derived from human stem cells.
  • 3‑D Bioprinting: Layer‑by‑layer printing of living tissue structures.
  • In‑silico models: AI‑driven simulations predicting drug‑body interactions.
  • Ex‑vivo systems: Human tissues kept alive outside the body for short‑term testing.

Advantages: Higher predictive accuracy, cost & time efficiency, enables precision medicine, and aligns with ethical standards.

Prepared for UPSC Civil Services Examination – GS Paper 2 & 3